Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis

Heng Lin, Chun Cheng Hou, Ching Feng Cheng, Ted H. Chiu, Yung Ho Hsu, Yuh Mou Sue, Tso Hsiao Chen, Hsin Han Hou, Ying Chi Chao, Tzu Hurng Cheng, Cheng Hsien Chen

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor-α (PPAR-α) is a transcription factor and has been reported to inhibit cisplatin-mediated proximal tubule cell death. In addition, doxorubicin (Adriamycin)-induced nephrosis in rats is a commonly used experimental model for pharmacological studies of human chronic renal diseases. In this study, we investigated the protective effect of PPAR-α on doxorubicin-induced apoptosis and its detailed mechanism in NRK-52E cells and animal models. The mRNA level of PPAR-α was found to be reduced by doxorubicin treatment in NRK-52E cells. PPAR-α overexpression in NRK-52E cells significantly inhibited doxorubicin-induced apoptosis and the quantity of cleaved caspase-3. Endogenous prostacyclin (PGI2) augmentation, which has been reported to protect NRK-52E cells from doxorubicin-induced apoptosis, induced the translocation and activation of PPAR-α. The transformation of PPAR-α short interfering RNA was applied to silence the PPAR-αgene, which abolished the protective effect of PGI2 augmentation in doxorubicin-treated cells. To confirm the protective role of PPAR-α in vivo, PPAR-α activator docosahexaenoic acid (DHA) was administered to doxorubicin-treated mice, and it has been shown to significantly reduce the doxorubicin-induced apoptotic cells in renal cortex. However, this protective effect of DHA did not exist in PPAR-α-deficient mice. In NRK-52E cells, the overexpression of PPAR-α elevated the activity of catalase and superoxide dismutase and inhibited doxorubicin-induced reactive oxygen species (ROS). PPAR-α overexpression also inhibited the doxorubicin-induced activity of nuclear factor-κB (NF-κB), which was associated with the interaction between PPAR-α and NF-κB p65 subunit as revealed in immunoprecipitation assays. Therefore, PPAR-α is capable of inhibiting doxorubicin-induced ROS and NF-κB activity and protecting NRK-52E cells from doxorubicin-induced apoptosis.

Original languageEnglish
Pages (from-to)1238-1245
Number of pages8
JournalMolecular Pharmacology
Volume72
Issue number5
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Peroxisome Proliferator-Activated Receptors
Doxorubicin
Apoptosis
Kidney
Epoprostenol
Docosahexaenoic Acids
Reactive Oxygen Species
Nephrosis
Chronic Renal Insufficiency
Immunoprecipitation
Caspase 3
Catalase
Small Interfering RNA
Cisplatin
Superoxide Dismutase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis. / Lin, Heng; Hou, Chun Cheng; Cheng, Ching Feng; Chiu, Ted H.; Hsu, Yung Ho; Sue, Yuh Mou; Chen, Tso Hsiao; Hou, Hsin Han; Chao, Ying Chi; Cheng, Tzu Hurng; Chen, Cheng Hsien.

In: Molecular Pharmacology, Vol. 72, No. 5, 11.2007, p. 1238-1245.

Research output: Contribution to journalArticle

Lin, Heng ; Hou, Chun Cheng ; Cheng, Ching Feng ; Chiu, Ted H. ; Hsu, Yung Ho ; Sue, Yuh Mou ; Chen, Tso Hsiao ; Hou, Hsin Han ; Chao, Ying Chi ; Cheng, Tzu Hurng ; Chen, Cheng Hsien. / Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis. In: Molecular Pharmacology. 2007 ; Vol. 72, No. 5. pp. 1238-1245.
@article{040ad8019a9644b29d04430f5b4e56c7,
title = "Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis",
abstract = "Peroxisome proliferator-activated receptor-α (PPAR-α) is a transcription factor and has been reported to inhibit cisplatin-mediated proximal tubule cell death. In addition, doxorubicin (Adriamycin)-induced nephrosis in rats is a commonly used experimental model for pharmacological studies of human chronic renal diseases. In this study, we investigated the protective effect of PPAR-α on doxorubicin-induced apoptosis and its detailed mechanism in NRK-52E cells and animal models. The mRNA level of PPAR-α was found to be reduced by doxorubicin treatment in NRK-52E cells. PPAR-α overexpression in NRK-52E cells significantly inhibited doxorubicin-induced apoptosis and the quantity of cleaved caspase-3. Endogenous prostacyclin (PGI2) augmentation, which has been reported to protect NRK-52E cells from doxorubicin-induced apoptosis, induced the translocation and activation of PPAR-α. The transformation of PPAR-α short interfering RNA was applied to silence the PPAR-αgene, which abolished the protective effect of PGI2 augmentation in doxorubicin-treated cells. To confirm the protective role of PPAR-α in vivo, PPAR-α activator docosahexaenoic acid (DHA) was administered to doxorubicin-treated mice, and it has been shown to significantly reduce the doxorubicin-induced apoptotic cells in renal cortex. However, this protective effect of DHA did not exist in PPAR-α-deficient mice. In NRK-52E cells, the overexpression of PPAR-α elevated the activity of catalase and superoxide dismutase and inhibited doxorubicin-induced reactive oxygen species (ROS). PPAR-α overexpression also inhibited the doxorubicin-induced activity of nuclear factor-κB (NF-κB), which was associated with the interaction between PPAR-α and NF-κB p65 subunit as revealed in immunoprecipitation assays. Therefore, PPAR-α is capable of inhibiting doxorubicin-induced ROS and NF-κB activity and protecting NRK-52E cells from doxorubicin-induced apoptosis.",
author = "Heng Lin and Hou, {Chun Cheng} and Cheng, {Ching Feng} and Chiu, {Ted H.} and Hsu, {Yung Ho} and Sue, {Yuh Mou} and Chen, {Tso Hsiao} and Hou, {Hsin Han} and Chao, {Ying Chi} and Cheng, {Tzu Hurng} and Chen, {Cheng Hsien}",
year = "2007",
month = "11",
doi = "10.1124/mol.107.037523",
language = "English",
volume = "72",
pages = "1238--1245",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis

AU - Lin, Heng

AU - Hou, Chun Cheng

AU - Cheng, Ching Feng

AU - Chiu, Ted H.

AU - Hsu, Yung Ho

AU - Sue, Yuh Mou

AU - Chen, Tso Hsiao

AU - Hou, Hsin Han

AU - Chao, Ying Chi

AU - Cheng, Tzu Hurng

AU - Chen, Cheng Hsien

PY - 2007/11

Y1 - 2007/11

N2 - Peroxisome proliferator-activated receptor-α (PPAR-α) is a transcription factor and has been reported to inhibit cisplatin-mediated proximal tubule cell death. In addition, doxorubicin (Adriamycin)-induced nephrosis in rats is a commonly used experimental model for pharmacological studies of human chronic renal diseases. In this study, we investigated the protective effect of PPAR-α on doxorubicin-induced apoptosis and its detailed mechanism in NRK-52E cells and animal models. The mRNA level of PPAR-α was found to be reduced by doxorubicin treatment in NRK-52E cells. PPAR-α overexpression in NRK-52E cells significantly inhibited doxorubicin-induced apoptosis and the quantity of cleaved caspase-3. Endogenous prostacyclin (PGI2) augmentation, which has been reported to protect NRK-52E cells from doxorubicin-induced apoptosis, induced the translocation and activation of PPAR-α. The transformation of PPAR-α short interfering RNA was applied to silence the PPAR-αgene, which abolished the protective effect of PGI2 augmentation in doxorubicin-treated cells. To confirm the protective role of PPAR-α in vivo, PPAR-α activator docosahexaenoic acid (DHA) was administered to doxorubicin-treated mice, and it has been shown to significantly reduce the doxorubicin-induced apoptotic cells in renal cortex. However, this protective effect of DHA did not exist in PPAR-α-deficient mice. In NRK-52E cells, the overexpression of PPAR-α elevated the activity of catalase and superoxide dismutase and inhibited doxorubicin-induced reactive oxygen species (ROS). PPAR-α overexpression also inhibited the doxorubicin-induced activity of nuclear factor-κB (NF-κB), which was associated with the interaction between PPAR-α and NF-κB p65 subunit as revealed in immunoprecipitation assays. Therefore, PPAR-α is capable of inhibiting doxorubicin-induced ROS and NF-κB activity and protecting NRK-52E cells from doxorubicin-induced apoptosis.

AB - Peroxisome proliferator-activated receptor-α (PPAR-α) is a transcription factor and has been reported to inhibit cisplatin-mediated proximal tubule cell death. In addition, doxorubicin (Adriamycin)-induced nephrosis in rats is a commonly used experimental model for pharmacological studies of human chronic renal diseases. In this study, we investigated the protective effect of PPAR-α on doxorubicin-induced apoptosis and its detailed mechanism in NRK-52E cells and animal models. The mRNA level of PPAR-α was found to be reduced by doxorubicin treatment in NRK-52E cells. PPAR-α overexpression in NRK-52E cells significantly inhibited doxorubicin-induced apoptosis and the quantity of cleaved caspase-3. Endogenous prostacyclin (PGI2) augmentation, which has been reported to protect NRK-52E cells from doxorubicin-induced apoptosis, induced the translocation and activation of PPAR-α. The transformation of PPAR-α short interfering RNA was applied to silence the PPAR-αgene, which abolished the protective effect of PGI2 augmentation in doxorubicin-treated cells. To confirm the protective role of PPAR-α in vivo, PPAR-α activator docosahexaenoic acid (DHA) was administered to doxorubicin-treated mice, and it has been shown to significantly reduce the doxorubicin-induced apoptotic cells in renal cortex. However, this protective effect of DHA did not exist in PPAR-α-deficient mice. In NRK-52E cells, the overexpression of PPAR-α elevated the activity of catalase and superoxide dismutase and inhibited doxorubicin-induced reactive oxygen species (ROS). PPAR-α overexpression also inhibited the doxorubicin-induced activity of nuclear factor-κB (NF-κB), which was associated with the interaction between PPAR-α and NF-κB p65 subunit as revealed in immunoprecipitation assays. Therefore, PPAR-α is capable of inhibiting doxorubicin-induced ROS and NF-κB activity and protecting NRK-52E cells from doxorubicin-induced apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=35548981840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548981840&partnerID=8YFLogxK

U2 - 10.1124/mol.107.037523

DO - 10.1124/mol.107.037523

M3 - Article

C2 - 17671096

AN - SCOPUS:35548981840

VL - 72

SP - 1238

EP - 1245

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -